Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Update

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) saw a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 4,330,000 shares, a decline of 7.3% from the January 15th total of 4,670,000 shares. Based on an average daily volume of 826,100 shares, the days-to-cover ratio is currently 5.2 days.

Institutional Trading of Fulcrum Therapeutics

Hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets acquired a new stake in shares of Fulcrum Therapeutics during the fourth quarter worth approximately $38,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Fulcrum Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company's stock worth $43,000 after buying an additional 4,701 shares in the last quarter. Mariner LLC acquired a new stake in shares of Fulcrum Therapeutics during the fourth quarter worth approximately $78,000. Walleye Capital LLC acquired a new stake in shares of Fulcrum Therapeutics during the third quarter worth approximately $59,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Fulcrum Therapeutics during the third quarter worth approximately $62,000. Institutional investors and hedge funds own 89.83% of the company's stock.

Fulcrum Therapeutics Trading Up 0.1 %

NASDAQ:FULC traded up $0.01 during mid-day trading on Friday, hitting $3.86. The company's stock had a trading volume of 283,505 shares, compared to its average volume of 458,874. Fulcrum Therapeutics has a fifty-two week low of $2.86 and a fifty-two week high of $13.70. The company has a market capitalization of $207.94 million, a price-to-earnings ratio of -12.44 and a beta of 2.03. The stock has a fifty day moving average of $4.19 and a 200-day moving average of $4.78.

Remove Ads

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on FULC. HC Wainwright reaffirmed a "neutral" rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th. Royal Bank of Canada restated a "sector perform" rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Fulcrum Therapeutics has a consensus rating of "Hold" and an average price target of $9.33.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.